These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 22947131)
21. A comparison of dry powder inhaler dose delivery characteristics using a power criterion. Dunbar CA; Morgan B; Van Oort M ; Hickey AJ PDA J Pharm Sci Technol; 2000; 54(6):478-84. PubMed ID: 11107840 [TBL] [Abstract][Full Text] [Related]
22. The inhalation characteristics of patients when they use different dry powder inhalers. Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999 [TBL] [Abstract][Full Text] [Related]
23. Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers. Ung KT; Chan HK Eur J Pharm Sci; 2016 Mar; 84():46-54. PubMed ID: 26780380 [TBL] [Abstract][Full Text] [Related]
24. Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder. Cai X; Yang Y; Xie X; Yu F; Yang Y; Yang Z; Zhang T; Mei X Drug Deliv; 2016 Jul; 23(6):1962-71. PubMed ID: 26066037 [TBL] [Abstract][Full Text] [Related]
26. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder. Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621 [TBL] [Abstract][Full Text] [Related]
27. Use of Airway Replicas in Lung Delivery Applications. Golshahi L; Finlay WH; Wachtel H J Aerosol Med Pulm Drug Deliv; 2022 Apr; 35(2):61-72. PubMed ID: 35262408 [TBL] [Abstract][Full Text] [Related]
28. Scintigraphic evaluation of lung deposition with a novel inhaler device. Newman SP; Hirst PH; Pitcairn GR Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S12-4. PubMed ID: 11385810 [TBL] [Abstract][Full Text] [Related]
29. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. Byron PR; Hindle M; Lange CF; Longest PW; McRobbie D; Oldham MJ; Olsson B; Thiel CG; Wachtel H; Finlay WH J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S59-69. PubMed ID: 21133801 [TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees. Ali AMA; Zawbaa HM; Sayed OM; Harb HS; Saeed H; Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Salem MN; Rabea H; Wael W; Hussein RRS; Sarhan RM; Ramadan W; Madney YM; Abdelrahim MEA Int J Clin Pract; 2021 Mar; 75(3):e13764. PubMed ID: 33067907 [TBL] [Abstract][Full Text] [Related]
31. [The relationship between inspiratory pressure and flow through dry powder inhaler available in Japan]. Kondo T; Tanigaki T; Tazaki G; Watanabe H; Ishii H; Tsunoda T; Uruma T Arerugi; 2010 Aug; 59(8):950-5. PubMed ID: 20820136 [TBL] [Abstract][Full Text] [Related]
32. Bioequivalence of Two Tiotropium Dry Powder Inhalers and the Utility of Realistic Impactor Testing. Gobetti C; Dissanayake S; Shur J; Ganley W; Silva L; Salem I; Najib O; Harb U J Aerosol Med Pulm Drug Deliv; 2023 Oct; 36(5):257-267. PubMed ID: 37358626 [No Abstract] [Full Text] [Related]
33. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers. Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953 [TBL] [Abstract][Full Text] [Related]
34. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: the influence of flow and volume. Yakubu SI; Assi KH; Chrystyn H Int J Pharm; 2013 Oct; 455(1-2):213-8. PubMed ID: 23892154 [TBL] [Abstract][Full Text] [Related]
35. Idealhalers Versus Realhalers: Is It Possible to Bypass Deposition in the Upper Respiratory Tract? Weers JG; Son YJ; Glusker M; Haynes A; Huang D; Kadrichu N; Le J; Li X; Malcolmson R; Miller DP; Tarara TE; Ung K; Clark A J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):55-69. PubMed ID: 30481087 [TBL] [Abstract][Full Text] [Related]
36. In Vitro Tests for Aerosol Deposition. V: Using Realistic Testing to Estimate Variations in Aerosol Properties at the Trachea. Wei X; Hindle M; Delvadia RR; Byron PR J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):339-348. PubMed ID: 28332899 [TBL] [Abstract][Full Text] [Related]
37. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers. Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210 [TBL] [Abstract][Full Text] [Related]
38. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131 [TBL] [Abstract][Full Text] [Related]
39. Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer. Newman SP; Pitcairn GR; Adkin DA; Vidgren MT; Silvasti M J Aerosol Med; 2001; 14(2):217-25. PubMed ID: 11681653 [TBL] [Abstract][Full Text] [Related]
40. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. DeHaan WH; Finlay WH J Aerosol Med; 2001; 14(3):361-7. PubMed ID: 11693848 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]